<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131702</url>
  </required_header>
  <id_info>
    <org_study_id>02399</org_study_id>
    <nct_id>NCT01131702</nct_id>
  </id_info>
  <brief_title>Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>Randomized,2-way Crossover, Bioequivalence Study of Ranitidine 300 mg Tablets Zantac 300 mg Tablets Administered as 1 x 300 mg Tablet in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate and extent of absorption of ranitidine 300&#xD;
      mg tablets versus Zantac 300 mg tablets administered as 1 x 300 mg tablet under fasting&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compared the rate and extent of absorption of ranitidine 300 rng tablets versus&#xD;
      Zantac. The study products were administered as a single oral dose of 1 x 300 mg tablet using&#xD;
      a randomized, two-way crossover fasting study in non-smoker healthy volunteers with a washout&#xD;
      period of 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ranitidine Tablets, 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zantac Tablets, 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine</intervention_name>
    <description>Ranitidine Tablets, 300 mg</description>
    <arm_group_label>Ranitidine Tablets, 300 mg</arm_group_label>
    <arm_group_label>Zantac Tablets, 300 mg</arm_group_label>
    <other_name>Zantac 300 mg tablets of Glaxosmithkline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects enrolled in this study will be members of the community at large. The&#xD;
             recruitment advertisements may be done using different media (e.g. radio, newspaper,&#xD;
             Anapharm Inc. Web site. Anapharm Inc. volunteers' data base). Subjects must meet all&#xD;
             of the following criteria in order to be included in the study:&#xD;
&#xD;
               -  Subjects will be females and/or males, non-smokers, 18 years of age and older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects to whom any of the following applies will be excluded from the study:&#xD;
&#xD;
               -  Clinically significant illnesses within 4 weeks of the administration of study&#xD;
                  medication.&#xD;
&#xD;
               -  Clinically significant surgery within 4 weeks prior to the administration of the&#xD;
                  study medication.&#xD;
&#xD;
               -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
               -  Any reason which, in the opinion of the medical sub investigator would prevent&#xD;
                  the subject from participating in the study.&#xD;
&#xD;
               -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
               -  Positive urine drug screen at screening.&#xD;
&#xD;
               -  Positive testing for hepatitis B, hepatitis C or HIV at screening.&#xD;
&#xD;
               -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic&#xD;
                  blood pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower&#xD;
                  than 50 or over 90 mmHg; or heart rate less than 50 or over 100 bpm) at&#xD;
                  screening.&#xD;
&#xD;
               -  Subjects with BMI â‰¥ 30.0.&#xD;
&#xD;
               -  History of significant alcohol abuse within six months of the screening visit or&#xD;
                  any indication of the regular use of more than fourteen units of alcohol per week&#xD;
                  (1 Unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
               -  History of-drug abuse or use of illegal drugs: use of soft drugs (such as&#xD;
                  marijuana) within 3 months of the screening visit or hard drugs (such as cocaine,&#xD;
                  phencyclidine (PCP) and crack) within 1 year of the screening visit.&#xD;
&#xD;
               -  History of allergic reactions to ranitidine or other Hr receptor antagonists&#xD;
                  (e.g.cimetidine, famotidine, nizatidine).&#xD;
&#xD;
               -  History of allergic reactions to heparin.&#xD;
&#xD;
               -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
                  inducers: barbiturates. carbamazepine. phenytoin. glucocorticoids&#xD;
                  rifampin/rifabutin;examples of inhibitors: antidepressants, cimetidine,&#xD;
                  diltiazem, erythromycin ketoconazole, MAO inhibitors, neuroleptics, verapamil.&#xD;
                  quinidine) within 30 days prior to administration of the study medication.&#xD;
&#xD;
               -  Use of an investigational drug or participation in an investigational study&#xD;
                  within 30 days prior to administration of the study medication.&#xD;
&#xD;
               -  History or presence of any clinically significant gastrointestinal pathology&#xD;
                  (e.g. chronic diarrhea inflammatory bowel diseases)unresolved gastrointestinal&#xD;
                  symptoms (e.g.diarrhea, vomiting), liver or kidney disease or other conditions&#xD;
                  known to interfere with the absorption, distribution, metabolism or excretion of&#xD;
                  the drug.&#xD;
&#xD;
               -  Any history or presence of clinically significant neurological, endocrinal,&#xD;
                  cardiovascular,pulmonary, hematologic, immunologic, psychiatric or metabolic&#xD;
                  disease.&#xD;
&#xD;
               -  Use of prescription medication within 14 days prior to administration of study&#xD;
                  medication or over-the-counter products (including natural food supplements,&#xD;
                  vitamins, garlic as supplement) within 7 days prior to administration of study&#xD;
                  medication, except for topical products without systemic absorption.&#xD;
&#xD;
               -  Use of any tobacco products in the last 6 months.&#xD;
&#xD;
               -  Any food allergy, intolerance, restriction or special diet that, in the opinion&#xD;
                  of the medical sub investigator, contraindicates the subject's participation in&#xD;
                  this study.&#xD;
&#xD;
               -  Subjects who have had a depot injection or an implant of any drug 3 months prior&#xD;
                  to administration of study medication.&#xD;
&#xD;
               -  Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior&#xD;
                  to administration of the study medication as follows:&#xD;
&#xD;
               -  less than 300 niL of whole blood within 30 days or&#xD;
&#xD;
               -  300 mL to 500 mL of whole blood within 45 days or&#xD;
&#xD;
               -  more than 500 mL of whole blood within 56 days.&#xD;
&#xD;
               -  Subjects with history or known presence of porphyria.&#xD;
&#xD;
        Additional exclusion criteria for females only:&#xD;
&#xD;
          -  Breast-feeding subjects.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening (performed on all females).&#xD;
&#xD;
          -  Female subjects of childbearing potential who have had unprotected sexual intercourse&#xD;
             with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy&#xD;
             for at least 6 months) within 14 days prior to study drug administration. The&#xD;
             acceptable methods of contraception are:&#xD;
&#xD;
               -  Condom + spermicide&#xD;
&#xD;
               -  Diaphragm +spermicide&#xD;
&#xD;
               -  Intrauterine contraceptive device (placed at least 4 weeks prior to study drug&#xD;
                  administration).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bicrell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapbarm Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>June 8, 2010</last_update_submitted>
  <last_update_submitted_qc>June 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ramakrishna Bangaru/Assistant Manager</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Ranitidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

